The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
Open accessAbstract
Purpose: To compare the quality of life (QoL) of patients receiving oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) or gemcitabine as first-line chemotherapy and to assess whether pretreatment QoL predicts survival in patients with metastatic pancreatic cancer. Patients and Methods: Three hundred forty-two patients with performance status 0 or 1 were randomly assigned to receive FOLFIRINOX (oxaliplatin, 85 mg/m 2; irinotecan, 180 mg/m 2; leucovorin, 400 mg/m 2; and fluorouracil, 400 mg/m 2 bolus followed by 2,400 mg/m 2 46-hour continuous infusion, once every 2 weeks) or gemcitabine 1,000 mg/m 2 weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks. QoL was assessed using European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire C30 every 2 weeks. Results: Improvement in global health status (GHS; P < .001) was observed in the FOLFIRINOX arm and improvement in emotional functioning (P < .001) was observed in both arms, along with a decrease in pain, insomnia, anorexia, and constipation in both arms. A significant increase in diarrhea was observed in the FOLFIRINOX arm during the first 2 months of chemotherapy. Time until definitive deterioration ≥ 20 points was significantly longer for FOLFIRINOX compared with gemcitabine for GHS, physical, role, cognitive, and social functioning, and six symptom domains (fatigue, nausea/vomiting, pain, dyspnea, anorexia, and constipation). Physical functioning, constipation, and dyspnea were independent significant prognostic factors for survival with treatment arm, age older than 65 years, and low serum albumin. Conclusion: FOLFIRINOX significantly reduces QoL impairment compared with gemcitabine in patients with metastatic pancreatic cancer. Furthermore, baseline QoL scores improved estimation of survival probability when added to baseline clinical and demographic variables.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coefficient Alpha and the Internal Structure of Tests
Cronbach, L. J. (1951) · Psychometrika · doi:10.1007/bf02310555 · Cited by 43,931
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationFayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 4,019
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Rao, S. J. (2003) · Journal of the American Statistical Association · doi:10.1198/jasa.2003.s263 · Cited by 1,941
Quinten, C., Coens, C., Mauer, M., Comte, S., Sprangers, M. A., Cleeland, C., Osoba, D., Bjordal, K., & Bottomley, A. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70200-1 · Cited by 659
The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials
Gotay, C. C., Kawamoto, C. T., Bottomley, A., & Efficace, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3439 · Cited by 644
Burstein, H. J., Krilov, L., Aragon-Ching, J. B., Baxter, N. N., Chiorean, E. G., Chow, W. A., De Groot, J. F., Devine, S. M., DuBois, S. G., El-Deiry, W. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5292 · Cited by 601
Montazeri, A. (2009) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-7-102 · Cited by 568
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
(2011) · New England Journal of Medicine · doi:10.1056/nejmc1107627 · Cited by 428
Efficace, F., Bottomley, A., Coens, C., Steen, K. V., Conroy, T., Schöffski, P., Schmoll, H., Cutsem, E. V., & Köhne, C. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.07.025 · Cited by 143
Self-citationBonnetain, F., Dahan, L., Maillard, E., Ychou, M., Mitry, E., Hammel, P. R., Legoux, J.-L., Rougier, P. R., Bedenne, L., & Seitz, J. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.023 · Cited by 111
Self-citationFrench version of FACT-G: validation and comparison with other cancer-specific instruments
Conroy, T., Mercier, M., Bonneterre, J. M., Luporsi, É., Lefebvre, J. L., Lapeyre, M., Puyraveau, M., & Schraub, S. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.06.010 · Cited by 91
Self-citationRoth, B. J., Krilov, L., Adams, S., Aghajanian, C. A., Bach, P. B., Braiteh, F., Brose, M. S., Ellis, L. M., Erba, H. P., George, D. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1938 · Cited by 65
The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia.
Robinson, D. W., Eisenberg, D. F., Cella, D. F., Zhao, N., de Boer, C., & DeWitte, M. (2008) · PubMed · Cited by 58
Kris, M. G., Benowitz, S. I., Adams, S., Diller, L., Ganz, P. A., Kahlenberg, M. S., Le, Q., Markman, M. M., Masters, G. A., Newman, L. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2742 · Cited by 54
FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
Kim, R. D. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70237-0 · Cited by 48
Patient Satisfaction with Quality of Life as a Predictor of Survival in Pancreatic Cancer
Lis, C. G., Gupta, D., & Grutsch, J. F. (2006) · International Journal of Gastrointestinal Cancer · doi:10.1385/ijgc:37:1:35 · Cited by 35
Harrell, F., Jr. (1996) · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V., Czito, B., Del Chiaro, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,304
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Asbun, H., Bain, A., Behrman, S. W., Benson, A. B., Binder, E., Cardin, D. B., Cha, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0131 · Cited by 1,020
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 610
de Sousa Cavalcante, L., & Monteiro, G. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.041 · Cited by 576
Metadata
- Authors
- Gourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Boige, V., Bérille, J., & Conroy, T.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-01-01
- Volume
- 31
- Issue
- 1
- Pages
- 23-29
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2164286021
- Cited by
- 501
- References
- 21
- FWCI
- 15.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.